Clinical Features and Sulfonylurea Usage Among Outpatients with Diabetes Aged ≥90 years in an Urban Diabetes Clinic in Tokyo

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2022 Sep 19

PMID 36121186

Authors

Toshiko Kobori

Yukiko Onishi

Yoko Yoshida

Tazu Tahara

Takako Kikuchi

Tetsuya Kubota

Masahiko Iwamoto

Shoko Hamano

Masato Kasuga

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Aging of society is accelerating in many countries. The purpose of this study was to describe the clinical features and sulfonylurea usage among diabetes outpatients aged ≥90 years (nonagenarians).

Materials And Methods: This study was a retrospective observational study. The study population consisted of 69 nonagenarian diabetes outpatients and 857 diabetes outpatients aged <90 years. Patients were classified into four groups: group 1, <65 years; group 2, 65-74 years; group 3, 75-89 years; and group 4, ≥90 years. The presence of hypoglycemic episodes was defined as having self-reported symptoms, or self-monitored or clinically measured blood glucose level <70 mg/dL.

Results: The median glycated hemoglobin (HbA1c) in group 1 and group 4 was 7.0% and 7.2%, respectively (P = 0.506). The proportion of sulfonylurea treatment in group 4 was 45.5%, which is significantly higher compared with the other three groups (20.0-27.8%, P < 0.001). In group 4, there was no difference between patients with or without sulfonylurea in age, sex, body mass index, HbA1c and number of antihyperglycemic agents. Five out of 25 nonagenarian sulfonylurea-treated patients had hypoglycemic episodes within the last 2 years, their HbA1c were all 7.0 ≤ HbA1c < 8.0, and sulfonylurea or insulin was tapered in all cases after confirming hypoglycemia. Tapering dosage was attempted in all 25 sulfonylurea-treated nonagenarian patients, but 15 needed to continue sulfonylurea for glycemic control, and 10 continued sulfonylurea with unknown reasons from their medical records.

Conclusions: Although tapering the dosage of sulfonylurea was attempted in nonagenarian patients, sulfonylurea was widely continued for glycemic control. Reverse clinical inertia may exist in some sulfonylurea-treated nonagenarian patients.

References

Phillips L, Branch W, COOK C, Doyle J, Gallina D, Miller C . Clinical inertia. Ann Intern Med. 2001; 135(9):825-34. DOI: 10.7326/0003-4819-135-9-200111060-00012. View

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H . Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int. 2020; 11(3):165-223. PMC: 7387396. DOI: 10.1007/s13340-020-00439-5. View

Ouchi Y, Rakugi H, Arai H, Akishita M, Ito H, Toba K . Redefining the elderly as aged 75 years and older: Proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017; 17(7):1045-1047. DOI: 10.1111/ggi.13118. View

van Mark G, Tittel S, Sziegoleit S, Putz F, Durmaz M, Bortscheller M . Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases. Ther Adv Endocrinol Metab. 2020; 11:2042018820958296. PMC: 7509713. DOI: 10.1177/2042018820958296. View

Salinero-Fort M, Mostaza-Prieto J, Lahoz-Rallo C, Vicente Diez J, Cardenas-Valladolid J . Population-based cross-sectional study of 11 645 Spanish nonagenarians with type 2 diabetes mellitus: cardiovascular profile, cardiovascular preventive therapies, achievement goals and sex differences. BMJ Open. 2019; 9(9):e030344. PMC: 6756452. DOI: 10.1136/bmjopen-2019-030344. View

. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S195-S207. PMC: 8935395. DOI: 10.2337/dc22-S013. View

Whelton P, Carey R, Aronow W, Casey Jr D, Collins K, Himmelfarb C . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on.... Hypertension. 2017; 71(6):e13-e115. DOI: 10.1161/HYP.0000000000000065. View

Shorr R, Ray W, Daugherty J, Griffin M . Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157(15):1681-6. View

Giugliano D, Esposito K . Clinical inertia as a clinical safeguard. JAMA. 2011; 305(15):1591-2. DOI: 10.1001/jama.2011.490. View

10.

Matsuoka A, Hirota Y, Takeda A, Kishi M, Hashimoto N, Ohara T . Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study. J Diabetes Investig. 2019; 11(2):417-425. PMC: 7078100. DOI: 10.1111/jdi.13132. View

11.

Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019; 42(9):1235-1481. DOI: 10.1038/s41440-019-0284-9. View

12.

Dahlen A, Dashi G, Maslov I, Attwood M, Jonsson J, Trukhan V . Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Front Pharmacol. 2022; 12:807548. PMC: 8807560. DOI: 10.3389/fphar.2021.807548. View

13.

. Committee Report: Glycemic targets for elderly patients with diabetes: Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. J Diabetes Investig. 2017; 8(1):126-128. PMC: 5217949. DOI: 10.1111/jdi.12599. View

14.

Ross S . Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013; 126(9 Suppl 1):S38-48. DOI: 10.1016/j.amjmed.2013.06.012. View

15.

Ross S, Tildesley H, Ashkenas J . Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011; 27 Suppl 3:13-20. DOI: 10.1185/03007995.2011.621416. View

16.

Moller J, Pedersen M, Tanaka H, Ohsugi M, Overgaard R, Lynge J . Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2013; 37(3):796-804. DOI: 10.2337/dc13-0598. View

17.

Blonde L, Aschner P, Bailey C, Ji L, Leiter L, Matthaei S . Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diab Vasc Dis Res. 2017; 14(3):172-183. PMC: 5418936. DOI: 10.1177/1479164116679775. View

18.

Viswanathan M, Mohan A, Ranjit U, Prasanna Kumar G, Philips R, Saravanan J . Clinical Profile of Elderly Patients (Over 90 Years) with Type 2 Diabetes Seen at a Diabetes Center in South India. Diabetes Technol Ther. 2019; 22(2):79-84. DOI: 10.1089/dia.2019.0219. View

19.

Giugliano D, Maiorino M, Bellastella G, Esposito K . Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. J Endocrinol Invest. 2018; 42(5):495-503. DOI: 10.1007/s40618-018-0951-8. View

20.

Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P . Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5):682-9. PMC: 3433794. DOI: 10.1111/j.1464-5491.2012.03605.x. View